{"@context":{"@vocab":"https://cir.nii.ac.jp/schema/1.0/","rdfs":"http://www.w3.org/2000/01/rdf-schema#","dc":"http://purl.org/dc/elements/1.1/","dcterms":"http://purl.org/dc/terms/","foaf":"http://xmlns.com/foaf/0.1/","prism":"http://prismstandard.org/namespaces/basic/2.0/","cinii":"http://ci.nii.ac.jp/ns/1.0/","datacite":"https://schema.datacite.org/meta/kernel-4/","ndl":"http://ndl.go.jp/dcndl/terms/","jpcoar":"https://github.com/JPCOAR/schema/blob/master/2.0/"},"@id":"https://cir.nii.ac.jp/crid/1360574094871660160.json","@type":"Article","productIdentifier":[{"identifier":{"@type":"DOI","@value":"10.1016/j.lungcan.2016.05.031"}},{"identifier":{"@type":"URI","@value":"https://api.elsevier.com/content/article/PII:S0169500216303579?httpAccept=text/xml"}},{"identifier":{"@type":"URI","@value":"https://api.elsevier.com/content/article/PII:S0169500216303579?httpAccept=text/plain"}}],"dc:title":[{"@value":"Intracranial response to nivolumab in NSCLC patients with untreated or progressing CNS metastases"}],"creator":[{"@id":"https://cir.nii.ac.jp/crid/1380574094871660163","@type":"Researcher","foaf:name":[{"@value":"Elizabeth Dudnik"}]},{"@id":"https://cir.nii.ac.jp/crid/1380574094871660164","@type":"Researcher","foaf:name":[{"@value":"Shlomit Yust-Katz"}]},{"@id":"https://cir.nii.ac.jp/crid/1380574094871660160","@type":"Researcher","foaf:name":[{"@value":"Hovav Nechushtan"}]},{"@id":"https://cir.nii.ac.jp/crid/1380574094871660161","@type":"Researcher","foaf:name":[{"@value":"Daniel A. Goldstein"}]},{"@id":"https://cir.nii.ac.jp/crid/1380574094871660166","@type":"Researcher","foaf:name":[{"@value":"Alona Zer"}]},{"@id":"https://cir.nii.ac.jp/crid/1380574094871660162","@type":"Researcher","foaf:name":[{"@value":"Dov Flex"}]},{"@id":"https://cir.nii.ac.jp/crid/1380574094871660165","@type":"Researcher","foaf:name":[{"@value":"Tali Siegal"}]},{"@id":"https://cir.nii.ac.jp/crid/1380574094871660167","@type":"Researcher","foaf:name":[{"@value":"Nir Peled"}]}],"publication":{"publicationIdentifier":[{"@type":"PISSN","@value":"01695002"},{"@type":"PISSN","@value":"http://id.crossref.org/issn/01695002"}],"prism:publicationName":[{"@value":"Lung Cancer"}],"dc:publisher":[{"@value":"Elsevier BV"}],"prism:publicationDate":"2016-08","prism:volume":"98","prism:startingPage":"114","prism:endingPage":"117"},"reviewed":"false","dc:rights":["https://www.elsevier.com/tdm/userlicense/1.0/"],"url":[{"@id":"https://api.elsevier.com/content/article/PII:S0169500216303579?httpAccept=text/xml"},{"@id":"https://api.elsevier.com/content/article/PII:S0169500216303579?httpAccept=text/plain"}],"createdAt":"2016-05-31","modifiedAt":"2020-09-21","relatedProduct":[{"@id":"https://cir.nii.ac.jp/crid/1360848656994948992","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Real-world Efficacy and Safety of Nivolumab for Advanced Non–Small-cell Lung Cancer: A Retrospective Multicenter Analysis"}]},{"@id":"https://cir.nii.ac.jp/crid/1390564238039472128","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Intracranial Response to Nivolumab in a Patient with PD-L1-negative Lung Adenocarcinoma"}]}],"dataSourceIdentifier":[{"@type":"CROSSREF","@value":"10.1016/j.lungcan.2016.05.031"},{"@type":"CROSSREF","@value":"10.1016/j.cllc.2018.01.001_references_DOI_S9bXdmjAWVvye76C6wcgWo21fFK"},{"@type":"CROSSREF","@value":"10.2169/internalmedicine.9884-17_references_DOI_S9bXdmjAWVvye76C6wcgWo21fFK"}]}